Overview

68Ga-DOTATATE PET/CT in Neuroendocrine Tumor

Status:
Recruiting
Trial end date:
2022-01-30
Target enrollment:
Participant gender:
Summary
Somatostatin receptor(SSTR) was expressed in neuroendocrine tumor cells and SSTR-targeting molecular imaging(68Ga-DOTATATE PET/CT) could be a promising technique to evaluate the primary tumor and metastatic lesions of neuroendocrine tumors with higher accuracy. This prospective study is going to investigate whether radiolabeled somatostatin analogs 68Ga-DOTATATE PET/CT may be valuable for diagnosis, risk stratification, and prognostic evaluation of neuroendocrine tumors and compared it with 18F-FDG PET/CT.
Phase:
Early Phase 1
Details
Lead Sponsor:
Peking Union Medical College Hospital